| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Razobazam targets the central nervous system to enhance cognitive function. As a benzodiazepine derivative, it likely interacts with GABA-A receptors or related CNS targets, though its specific binding site is not fully characterized. It produces nootropic effects in animal studies.
|
|---|---|
| ln Vitro |
In vitro, razobazam demonstrates effects on neuronal activity consistent with cognitive enhancement. It has been studied in brain tissue for its effects on neuronal density and metabolic activity. The compound increases neuronal density in the frontal cortex by 13%.
|
| ln Vivo |
In vivo, razobazam improves learning performance in socially deprived rats, showing an 18% increase in avoidance scores post-training. It induces significant changes in brain optical density, including a 22% decrease in the lateral habenula, a 25% increase in the ventral tegmental area, and a 13% increase in the prefrontal cortex.
|
| Enzyme Assay |
In vitro receptor binding assays use membrane preparations from brain tissue expressing GABA-A receptors or other benzodiazepine targets. Radiolabeled ligands such as [³H]flunitrazepam are used as tracers. Varying concentrations of razobazam are incubated with membranes, and bound radioactivity is measured by filtration or scintillation counting.
|
| Cell Assay |
In vitro cell-based assays evaluate razobazam in neuronal cell cultures. Cells are treated with the compound, and neuronal activity, calcium signaling, or receptor modulation is assessed. Cytotoxicity is evaluated using standard viability assays. Receptor binding studies may use receptor-expressing cell lines.
|
| Animal Protocol |
In vivo animal studies use socially deprived rat models. Rats are administered razobazam, and learning performance is assessed using active avoidance tests. Brain metabolic activity is measured by 2-deoxyglucose uptake. Optical density changes in specific brain regions (lateral habenula, ventral tegmental area, prefrontal cortex) are quantified.
|
| References |
| Molecular Formula |
C14H14N4O2
|
|---|---|
| Molecular Weight |
270.29
|
| Exact Mass |
270.112
|
| CAS # |
78466-98-5
|
| PubChem CID |
71228
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.343g/cm3
|
| Boiling Point |
706.3ºC at 760 mmHg
|
| Flash Point |
380.9ºC
|
| Index of Refraction |
1.638
|
| LogP |
1.879
|
| tPSA |
69.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
20
|
| Complexity |
408
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C2C(=NN1)N(C(=O)CC(=O)N2C3=CC=CC=C3)C
|
| InChi Key |
RHZDHINXKVZTEF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H14N4O2/c1-9-13-14(16-15-9)17(2)11(19)8-12(20)18(13)10-6-4-3-5-7-10/h3-7H,8H2,1-2H3,(H,15,16)
|
| Chemical Name |
3,8-dimethyl-4-phenyl-4,8-dihydropyrazolo[3,4-b][1,4]diazepine-5,7(1H,6H)-dione
|
| Synonyms |
Razobazamum Razobazam
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6997 mL | 18.4986 mL | 36.9973 mL | |
| 5 mM | 0.7399 mL | 3.6997 mL | 7.3995 mL | |
| 10 mM | 0.3700 mL | 1.8499 mL | 3.6997 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
